Relevant bibliographies by topics / Injectable opioid

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Injectable opioid'

Author: Grafiati
Published: 5 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Injectable opioid.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Injectable opioid"

1

Rodriguez-Monguio, Rosa, Mahim Naveed, and Enrique Seoane-Vazquez. "Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece?" PLOS ONE 16, no. 3 (2021): e0249274. http://dx.doi.org/10.1371/journal.pone.0249274.

Full text
Abstract:
Background Shortages of opioid analgesics are increasingly common, interfere with patient care and increase healthcare cost. This study characterized the incidence of shortages of opioid analgesics in the period 2015–2019 and evaluated potential predictors to forecast the risk of shortages. Methods This was an observational retrospective study using the US Food and Drug Administration (FDA) drug shortages data. All FDA approved opioids were included in the study. Opioid analgesics were identified using the FDA National Drug Codes (NDC) and classified according to the Drug Enforcement Administr
APA, Harvard, Vancouver, ISO, and other styles
2

Kjome, Kimberly L., and F. Gerard Moeller. "Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence." Substance Abuse: Research and Treatment 5 (January 2011): SART.S5452. http://dx.doi.org/10.4137/sart.s5452.

Full text
Abstract:
Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone. Treatment with oral naltrexone has been limited by poor treatment adherence and relapse. Studies with long-acting formulations have shown increased treatment adherence. Extended-release injectable naltrexone has been used for the treatment of alcohol dependence, and has recently received an indication for treatment of opioid dependence from the US Food and Drug Administrat
APA, Harvard, Vancouver, ISO, and other styles
3

El-Khoury, Joseph, and Andrew McBride. "Injectable opioid prescribing in Oxfordshire." Psychiatric Bulletin 33, no. 7 (2009): 277. http://dx.doi.org/10.1192/pb.33.7.277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Byford, Sarah, Barbara Barrett, Nicola Metrebian, et al. "Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction." British Journal of Psychiatry 203, no. 5 (2013): 341–49. http://dx.doi.org/10.1192/bjp.bp.112.111583.

Full text
Abstract:
BackgroundDespite evidence of the effectiveness of injectable opioid treatment compared with oral methadone for chronic heroin addiction, the additional cost of injectable treatment is considerable, and cost-effectiveness uncertain.AimsTo compare the cost-effectiveness of supervised injectable heroin and injectable methadone with optimised oral methadone for chronic refractory heroin addiction.MethodMultisite, open-label, randomised controlled trial. Outcomes were assessed in terms of quality-adjusted life-years (QALYs). Economic perspective included health, social services and criminal justic
APA, Harvard, Vancouver, ISO, and other styles
5

Noh, Yoojin, Kyu-Nam Heo, Yun Mi Yu, Ju-Yeun Lee, and Young-Mi Ah. "Trends in potentially inappropriate opioid prescribing and associated risk factors among Korean noncancer patients prescribed non-injectable opioid analgesics." Therapeutic Advances in Drug Safety 13 (January 2022): 204209862210910. http://dx.doi.org/10.1177/20420986221091001.

Full text
Abstract:
Introduction: The aim of this study was to investigate trends in the prevalence of potentially inappropriate opioid prescribing (PIOP) and identify potential risk factors among Korean noncancer patients. Methods: We conducted a cross-sectional study of annual national patient sample data from the Korean Health Insurance Review and Assessment Service (HIRA-NPS) for the period 2012–2018. Noncancer patients who were prescribed non-injectable opioid analgesics (NIOAs) at least once were included. The proportion of patients with at least one PIOP in terms of concurrent use of benzodiazepines or gab
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Zhengyan, Hongyu Xu, Yulin Zhu, et al. "Understanding the fate of an anesthetic, nalorphine upon interaction with human serum albumin: a photophysical and mass-spectroscopy approach." RSC Adv. 4, no. 48 (2014): 25410–19. http://dx.doi.org/10.1039/c4ra03541k.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

SPLETE, HEIDI. "Injectable Naltrexone Effective for Opioid Dependence." Internal Medicine News 44, no. 17 (2011): 40. http://dx.doi.org/10.1016/s1097-8690(11)70881-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Singh, Pooja, Kaylene Okada, Amelia Spinrad, Nancy Pire-Smerkanich, and Eunjoo Pacifici. "3570 The Regulatory Landscape of Products to Treat Opioid Overdose." Journal of Clinical and Translational Science 3, s1 (2019): 58–59. http://dx.doi.org/10.1017/cts.2019.138.

Full text
Abstract:
OBJECTIVES/SPECIFIC AIMS: Since 1971, Naloxone has been the only FDA approved opioid antagonist indicated for use after opioid overdose. New formulations of Naloxone have been introduced into the market, including an injectable, auto-injector, and nasal spray. However, Naloxone is short-acting and as such often requires multiple doses and may induce severe withdrawal symptoms. This study examines the regulatory framework to understand the evolution of products indicated to treat opioid overdose and the landscape of therapies in development. Furthermore, this study examines how the Food and Dru
APA, Harvard, Vancouver, ISO, and other styles
9

Bell, James, Vendula Belackova, and Nicholas Lintzeris. "Supervised Injectable Opioid Treatment for the Management of Opioid Dependence." Drugs 78, no. 13 (2018): 1339–52. http://dx.doi.org/10.1007/s40265-018-0962-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Drucker, Ernest. "Injectable heroin substitution treatment for opioid dependency." Lancet 358, no. 9291 (2001): 1385. http://dx.doi.org/10.1016/s0140-6736(01)06490-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Injectable opioid"

1

McDonald, Rebecca Silvia. "Non-injectable naloxone for the prevention of opioid overdose deaths." Thesis, King's College London (University of London), 2018. https://kclpure.kcl.ac.uk/portal/en/theses/noninjectable-naloxone-for-the-prevention-of-opioid-overdose-deaths(854e176a-6483-4f70-9340-b3806e03fb21).html.

Full text
Abstract:
Background and Aims: Naloxone is the standard treatment for reversal of opioid overdoses. Due to risk of needle-stick injury, licensed injectable naloxone products are not well suited for layperson administration or take-home naloxone distribution. The aims of this thesis are threefold: Aim 1) assess the effectiveness and limitations of take-home naloxone provision (any naloxone formulation); Aim 2) compare the pharmacokinetic profiles of non-injectable naloxone formulations; Aim 3) identify non-injectable formulations that provide early naloxone exposure similar to a 0.4mg intramuscular dose.
APA, Harvard, Vancouver, ISO, and other styles
2

Fournier, Charles. "L’association entre un binge de drogue et la tentative de suicide dans une population d’utilisateurs de drogues injectables." Thèse, 2018. http://hdl.handle.net/1866/22310.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Injectable opioid"

1

U. S. Department of Health and Human Services. Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide. Lulu Press, Inc., 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Injectable opioid"

1

Oviedo-Joekes, Eugenia. "Injectable Opioid Treatment." In The Oxford Handbook of Opioids and Opioid Use Disorder. Oxford University Press, 2023. http://dx.doi.org/10.1093/oxfordhb/9780197618431.013.22.

Full text
Abstract:
Abstract Worldwide, opioid use disorder (OUD) presents a major public health challenge, currently exacerbated by the opioid crisis and the COVID-19 pandemic. There is an urgent need to improve, innovate, and diversify the offer of opioid-assisted treatments to engage those currently still dependent on the illicit drug stream and who remain at greater risk of lethal and non-lethal harms. The provision of injectable opioid agonist therapy (iOAT) is feasible, safe, and effective for the treatment of OUD, and diversifies the available offer of opioid-assisted treatments to support service users in
APA, Harvard, Vancouver, ISO, and other styles
2

Rastegar, Darius A. "Opioids." In ASAM Handbook of Addiction Medicine. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780197506172.003.0006.

Full text
Abstract:
Opioids are a class of drugs that include heroin and prescription pain relievers that produce analgesia and euphoria. More than 2 million Americans have an opioid use disorder. Acute effects include analgesia, respiratory depression, miosis, and euphoria. Overdose is a serious complication of opioid use, characterized by depressed level of consciousness and respiratory depression. It can be treated with naloxone. Withdrawal symptoms include dysphoria, yawning, tearing, diarrhea, cramps, nausea, and piloerection. Buprenorphine, methadone, clonidine, and lofexidine can be used to ameliorate the
APA, Harvard, Vancouver, ISO, and other styles
3

Tsoy-Podosenin, Marina, and Evgeny Krupitsky. "Naltrexone." In The Oxford Handbook of Opioids and Opioid Use Disorder. Oxford University Press, 2023. http://dx.doi.org/10.1093/oxfordhb/9780197618431.013.38.

Full text
Abstract:
Abstract Use of opioid antagonists, particularly when delivered as an extended-release formulation, is a meaningful treatment option for individuals with opioid use disorder who are highly motivated to remain opioid abstinent or do not have access to agonist treatment. Current evidence suggests that use of injectable and implantable depot formulations of naltrexone is safe and well-tolerated. Initiation of an extended-release naltrexone remains a challenge for patients using opioid agonists and requires further development of rapid and effective methods of induction. When initiated, the extend
APA, Harvard, Vancouver, ISO, and other styles
4

Strain, Eric C., and Andrew Gaddis. "Buprenorphine." In The Oxford Handbook of Opioids and Opioid Use Disorder. Oxford University Press, 2023. http://dx.doi.org/10.1093/oxfordhb/9780197618431.013.19.

Full text
Abstract:
Abstract Buprenorphine is an opioid that acts primarily as a partial agonist at mu-opioid receptors, although it also has significant activity at kappa- and delta-, as well as ORL-1, opioid receptors. Early in its development it was noted to have an unusual profile of effects, including a bell-shaped dose response curve, and over 40 years ago it was identified as a potential treatment for opioid use disorder (OUD). While initially marketed as an analgesic, its major impact has been as a treatment for OUD. The extensive uptake for OUD reflects both the circumstances of its availability as a rel
APA, Harvard, Vancouver, ISO, and other styles
5

Cheetham, Ali, and Suzanne Nielsen. "Pharmacy-Based Treatment Options for Opioid Use Disorder." In The Oxford Handbook of Opioids and Opioid Use Disorder. Oxford University Press, 2023. http://dx.doi.org/10.1093/oxfordhb/9780197618431.013.29.

Full text
Abstract:
Abstract Community pharmacists can play in addressing opioid-related harm. Community pharmacists are one of the most accessible health care professionals, with 90% of the US population within 3 km (2 miles) of a community pharmacy, and similarly, in regional areas of Australia, 72% of people are within 2.5 km of a pharmacy. This chapter will conduct a narrative review of the history of the delivery of harm reduction interventions in community pharmacy, and more recent innovations in pharmacy settings which can contribute to the identification and treatment of opioid use disorders. Models of de
APA, Harvard, Vancouver, ISO, and other styles
6

Gold, Mark S., and Kenneth Blum. "Clonidine." In The Oxford Handbook of Opioids and Opioid Use Disorder. Oxford University Press, 2023. http://dx.doi.org/10.1093/oxfordhb/9780197618431.013.20.

Full text
Abstract:
Abstract Clonidine’s molecular mechanism of action is agonism at the alpha-2A receptor, a subtype of the alpha-2-adrenergic receptor, found principally within the prefrontal cortex (PFC), where it prevents the secretion of norepinephrine (NE). NE causes the symptoms of withdrawal. Thus, clonidine can treat withdrawal-related symptoms including anxiety, hypertension, and tachycardia. Gold and associates found they could reverse the effects of locus coeruleus stimulation with clonidine. This noradrenergic hypothesis for opioid withdrawal changed the field. The benefits of clonidine in the transi
APA, Harvard, Vancouver, ISO, and other styles
7

Peglow, Stephanie Lee, Joshua Moran, and Matthew Keats. "Antagonist Treatment for Opioid Use Disorder." In Substance Use Disorders. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780190920197.003.0010.

Full text
Abstract:
This chapter focuses on the use of oral and injectable extended-release naltrexone for opioid use disorder. The historical development of naltrexone and its pharmacology are discussed. The chapter presents the clinical application of initiating naltrexone therapy, including the transition to and from methadone and buprenorphine and the utility of the naloxone challenge test. The pros and cons of naltrexone are reviewed and compared to first-line agents: methadone and buprenorphine. In addition, the efficacy of different formulations of naltrexone is addressed. Last, this chapter reviews the us
APA, Harvard, Vancouver, ISO, and other styles
8

Bowles, Jeanette, Nazlee Maghsoudi MGA, Samantha Young, Sarah Griffiths, and Gillian Kolla. "The Effectiveness and Efficacy of Prescribed Diacetylmorphine (Heroin) in Reducing Drug-related Harm." In Evaluating the impact of Laws Regulating Illicit Drugs on Health and Society. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815079241123010007.

Full text
Abstract:
Opioid overdoses have dramatically increased throughout the past 20 years. Overdoses and other harms associated with the use of the unregulated opioid supply have resulted in a consortium of approaches to reduce drug-related harms, which for decades has included heroin-assisted treatment, although there remains widespread reticence to implement this approach in spite of ample evidence to support its effectiveness. Heroin-assisted treatment is often reserved for persons who have attempted standard opioid agonist treatments - such as methadone - unsuccessfully in order to be eligible for heroin-
APA, Harvard, Vancouver, ISO, and other styles
9

Lysyshyn, Mark, and Mark Tyndall. "Public Health Approaches to Overdose Prevention and Harm Reduction." In A Public Health Guide to Ending the Opioid Epidemic. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780190056810.003.0004.

Full text
Abstract:
Harm reduction aims to reduce the negative consequences of drug use in people unable or unwilling to stop. This chapter focus on harm reduction policies, programs, and practices that have been employed in Vancouver, British Columbia, including the controversial introduction of supervised injection sites. Using data from the Vancouver experience, the authors describe successful harm reduction efforts that have resulted in no overdose deaths in Vancouver’s supervised injection facilities. The authors stress that harm reduction approaches are meant to be complementary to prevention and treatment
APA, Harvard, Vancouver, ISO, and other styles
10

K, Dr Vijayareka. "EMERGING TRENDS IN DENTAL PHARMACOLOGY: NOVEL DRUG DEVELOPMENTS AND ADVANCEMENTS IN DRUG DELIVERY SYSTEMS FOR DENTAL PAIN MANAGEMENT." In Futuristic Trends in Medical Sciences Volume 3 Book 9. Iterative International Publisher, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bfms9p1ch5.

Full text
Abstract:
The field of dental pharmacology has witnessed significant advancements in recent years, offering promising solutions to enhance dental pain management and patient care. This chapter explores the latest emerging trends in dental pharmacology, focusing on novel drug developments and advancements in drug delivery systems tailored to improve the efficacy, safety, and patient experience in dental pain management. Firstly, we delve into the realm of novel drug developments for dental pain management. Traditionally, the armamentarium of dental analgesics has relied on local anesthetics, nonsteroidal
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Injectable opioid"

1

"METHADONE WITHDRAWAL PSYCHOSIS: A CLINICAL CASE." In 23° Congreso de la Sociedad Española de Patología Dual (SEPD) 2021. SEPD, 2021. http://dx.doi.org/10.17579/sepd2021p132v.

Full text
Abstract:
The purpose of this article is, through a clinical case, to review the literature on psychosis secondary to methadone withdrawal. Observation of the patient and consultation of the clinical file. Non-systematic literature review on methadone use, methadone discontinuation and dual pathology. A 47-year-old male, history of opioid and cannabinoid use disorder, currently in abstinence and under opioid substitution therapy with methadone. After abrupt discontinuation of methadone, he began presenting delusional ideas of jealousy and persecution with multiple delusional interpretations. A diagnosis
APA, Harvard, Vancouver, ISO, and other styles
2

"ADDICTION RECOVERY AMONG OPIOID-DEPENDENT PATIENTS TREATED WITH INJECTABLE DEPOT BUPRENORPHINE: AN INTERIM ANALYSIS." In 8th World Congress of the World Association of Dual Disorders (WADD) and the 26th Congress of the Spanish Society of Dual Disorders SEPD. SEPD/WADD, 2024. http://dx.doi.org/10.17579/abstractbookdualdisorders-co-019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Worthington, J., A. Allan, and K. Khanna. "42 Preparing intrathecal opioid injectate, a ‘tip’ for success." In ESRA 2021 Virtual Congress, 8–9–10 September 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/rapm-2021-esra.42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Injectable opioid' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography